Multiple genetic polymorphisms of GSTP1 313AG, MDR1 3435CC, and MTHFR 677CC highly correlated with early relapse of breast cancer patients in Taiwan

Annals of Surgical Oncology

Volumn 15, Issue 3, 2008, Pages 872-880

  Huang, Ming Yii ^a,b,c   Wang, Yi Hui ^a   Chen, Fang Ming ^a,b,c   Lee, Su Chen ^b   Fang, Wei Yu ^a   Cheng, Tian Lu ^a   Hou, Ming Feng ^b,c   Wang, Jaw Yuan ^b,c   Lin, Shiu Ru ^a  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Breast cancer; Early relapse; GSTP1; MDR1; MTHFR; Multiple genetic polymorphisms

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; GLUTATHIONE TRANSFERASE P1; THYMIDYLATE SYNTHASE;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; ARTICLE; BREAST CANCER; CANCER RELAPSE; CORRELATIONAL STUDY; FEMALE; GENE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MULTIDRUG RESISTANCE; MULTIPLE CYCLE TREATMENT; PATHOLOGY; POLYMERASE CHAIN REACTION; PROGNOSIS; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TAIWAN; TANDEM REPEAT; TREATMENT OUTCOME;

ADULT; AGED; BREAST NEOPLASMS; FEMALE; GLUTATHIONE S-TRANSFERASE PI; HUMANS; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; P-GLYCOPROTEIN; PILOT PROJECTS; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; RECURRENCE; TAIWAN; THYMIDYLATE SYNTHASE; TIME FACTORS;

EID: 39149141326     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-007-9719-7     Document Type: Article

References (26)

1. Combination adjuvant chemotherapy for node-positive breast cancer. Inadequacy of a single perioperative cycle. The Ludwig Breast Cancer Study Group. N Engl J Med 1988;319:677-83
2. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. Lancet 1992;339:1-15
3. Polychemotherapy for early breast cancer: An overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998;352:930-42
4. Keiling R, Armand PP, Hurteloup P, et al. [French FAC vs FEC study in advanced breast cancer]. Onkologie 1986;9:8-10
5. Lopez M, Papaldo P, Di Lauro L, et al. 5-Fluorouracil, adriamycin, cyclophosphamide (FAC) vs. 5-fluorouracil, epirubicin, cyclophosphamide (FEC) in metastatic breast cancer. Oncology 1989;46:1-5
6. Choi JY, Nowell SA, Blanco JG, et al. The role of genetic variability in drug metabolism pathways in breast cancer prognosis. Pharmacogenomics 2006;7:613-24
7. Evans WE, Relling MV. Pharmacogenomics: Translating functional genomics into rational therapeutics. Science 1999; 286:487-91
8. Zhong S, Huang M, Yang X, et al. Relationship of glutathione S-transferase genotypes with side-effects of pulsed cyclophosphamide therapy in patients with systemic lupus erythematosus. Br J Clin Pharmacol 2006; 62:457-72
9. Ambudkar SV, Dey S, Hrycyna CA, et al. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Ann Rev Pharmacol Toxicol 1999; 39:361-98
10. Weisberg IS, Jacques PF, Selhub J, et al. The 1298A->C polymorphism in methylenetetrahydrofolate reductase (MTHFR): In vitro expression and association with homocysteine. Atherosclerosis 2001; 156:409-15
11. Iacopetta B, Grieu F, Joseph D, Elsaleh H. A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil. Br J Cancer 2001; 85:827-30
12. International Union Against Cancer. TNM Classification of Malignant Tumors. 6th ed: New York: Wiley-Liss, Inc., 2002
13. Sweeney C, McClure GY, Fares MY, et al. Association between survival after treatment for breast cancer and glutathione S-transferase P1 Ile105Val polymorphism. Cancer Res 2000;60:5621-4
14. Egan KM, Cai Q, Shu XO, et al. Genetic polymorphisms in GSTM1, GSTP1, and GSTT1 and the risk for breast cancer: Results from the Shanghai Breast Cancer Study and meta-analysis. Cancer Epidemiol Biomarkers Prev 2004;13:197-204
15. Kim SU, Lee KM, Park SK, et al. Genetic polymorphism of glutathione S-transferase P1 and breast cancer risk. J Biochem Mol Biol 2004;37:582-5
16. Kafka A, Sauer G, Jaeger C, et al. Polymorphism C3435T of the MDR-1 gene predicts response to preoperative chemotherapy in locally advanced breast cancer. Int J Oncol 2003; 22:1117-21
17. Campbell IG, Baxter SW, Eccles DM, et al. Methylenetetrahydrofolate reductase polymorphism and susceptibility to breast cancer. Breast Cancer Res 2002;4:R14
18. Shrubsole MJ, Shu XO, Ruan ZX, et al. MTHFR genotypes and breast cancer survival after surgery and chemotherapy: A report from the Shanghai Breast Cancer Study. Breast Cancer Res Treat 2005;91:73-9
19. Lee SA, Kang D, Nishio H, et al. Methylenetetrahydrofolate reductase polymorphism, diet, and breast cancer in Korean women. Exp Mol Med 2004;36:116-21
20. Martin DN, Boersma BJ, Howe TM, et al. Association of MTHFR gene polymorphisms with breast cancer survival. BMC Cancer 2006;6:257
21. Le Marchand L, Haiman CA, Wilkens LR, et al. MTHFR polymorphisms, diet, HRT, and breast cancer risk: The multiethnic cohort study. Cancer Epidemiol Biomarkers Prev 2004;13:2071-7
22. Chou YC, Wu MH, Yu JC, et al. Genetic polymorphisms of the methylenetetrahydrofolate reductase gene, plasma folate levels and breast cancer susceptibility: A case-control study in Taiwan. Carcinogenesis 2006;27:2295-300
23. Zhai X, Gao J, Hu Z, et al. Polymorphisms in thymidylate synthase gene and susceptibility to breast cancer in a Chinese population: A case-control analysis. BMC Cancer 2006;6:138
24. Largillier R, Etienne-Grimaldi MC, Formento JL, et al. Pharmacogenetics of capecitabine in advanced breast cancer patients. Clin Cancer Res 2006;12:5496-502
25. Neri A, Marrelli D, Rossi S, et al. Breast cancer local recurrence: Risk factors and prognostic relevance of early time to recurrence. World J Surg 2007;31:36-45
26. Livi L, Paiar F, Saieva C, et al. Survival and breast relapse in 3834 patients with T1-T2 breast cancer after conserving surgery and adjuvant treatment. Radiother Oncol 2007;82:287-93